Advertisement
Screener

PROPANC BIOPHARMA, INC. (PPCB) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

PROPANC BIOPHARMA, INC. Stock-Based Compensation

PROPANC BIOPHARMA, INC. (PPCB) reported Stock-Based Compensation of $7.27 million for the 9-month period ending 2026-03-31, per its S-1 filed 2026-07-17.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-07-17

  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.77M.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.47M.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.02M.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $3.12M.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $2.41K, a 96.68% decline from fiscal 2022.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $72.51K, a 12.50% decline from fiscal 2021.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $82.87K, a 72.41% decline from fiscal 2020.
  • PROPANC BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $300.42K.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 51 monthShare-based Payment Arrangement, Noncash Expense 54 monthShare-based Payment Arrangement, Noncash Expense 57 monthShare-based Payment Arrangement, Noncash Expense 60 monthShare-based Payment Arrangement, Noncash Expense 63 monthShare-based Payment Arrangement, Noncash Expense 66 monthShare-based Payment Arrangement, Noncash Expense 68 monthShare-based Payment Arrangement, Noncash Expense 72 monthShare-based Payment Arrangement, Noncash Expense 75 monthShare-based Payment Arrangement, Noncash Expense 77 month
2026-03-31$1.77M
derived: S-1 9 month − S-1 6 month · filed 2026-07-17
$4.25M
derived: sum of 2 quarters · filed 2026-07-17
$7.27M
S-1 · filed 2026-07-17
$10.39M
derived: sum of 4 quarters · filed 2026-07-17
2025-12-31$2.47M
derived: S-1 6 month − 10-Q 3 month · filed 2026-04-10
$5.50M
S-1 · filed 2026-04-10
$8.61M
derived: sum of 3 quarters · filed 2026-07-17
2025-09-30$3.02M
10-Q · filed 2025-11-14
$6.14M
derived: sum of 2 quarters · filed 2026-07-17
2025-06-30$3.12M
derived: S-1 12 month − S-1 9 month · filed 2026-07-17
$4.62M
S-1 · filed 2026-07-17
2025-03-31$1.51M
S-1 · filed 2026-07-17
2023-06-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30
$0.00
derived: sum of 2 quarters · filed 2024-09-30
$0.00
derived: sum of 3 quarters · filed 2024-09-30
$2.41K
10-K · filed 2024-09-30
2023-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15
$0.00
derived: sum of 2 quarters · filed 2024-05-15
$2.41K
10-Q · filed 2024-05-15
$12.77K
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-20
$2.41K
10-Q · filed 2024-02-20
$12.77K
derived: sum of 3 quarters · filed 2024-02-20
$33.48K
derived: sum of 4 quarters · filed 2024-02-20
2022-09-30$2.41K
10-Q · filed 2023-11-14
$12.77K
derived: sum of 2 quarters · filed 2023-11-14
$33.48K
derived: sum of 3 quarters · filed 2023-11-14
$54.20K
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$10.36K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-28
$31.08K
derived: sum of 2 quarters · filed 2023-09-28
$51.80K
derived: sum of 3 quarters · filed 2023-09-28
$72.51K
10-K · filed 2023-09-28
2022-03-31$20.72K
10-Q · filed 2022-05-16
$41.44K
derived: sum of 2 quarters · filed 2022-05-16
$62.15K
10-Q · filed 2023-05-15
$82.87K
derived: sum of 4 quarters · filed 2022-11-14
2021-12-31$20.72K
10-Q · filed 2022-02-14
$41.44K
10-Q · filed 2023-02-10
$62.15K
derived: sum of 3 quarters · filed 2022-11-14
$82.87K
derived: sum of 4 quarters · filed 2022-11-14
2021-09-30$20.72K
10-Q · filed 2022-11-14
$41.44K
derived: sum of 2 quarters · filed 2022-11-14
$62.15K
derived: sum of 3 quarters · filed 2022-11-14
$82.87K
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$20.72K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-28
$41.44K
derived: sum of 2 quarters · filed 2022-09-28
$62.15K
derived: sum of 3 quarters · filed 2022-09-28
$82.87K
10-K · filed 2022-09-28
2021-03-31$20.72K
10-Q · filed 2022-05-16
$41.44K
derived: sum of 2 quarters · filed 2022-05-16
$62.15K
10-Q · filed 2022-05-16
$137.26K
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$20.72K
10-Q · filed 2022-02-14
$41.44K
10-Q · filed 2022-02-14
$116.54K
derived: sum of 3 quarters · filed 2022-02-14
$137.26K
derived: sum of 4 quarters · filed 2022-02-14
2020-09-30$20.72K
10-Q · filed 2021-11-12
$95.82K
derived: sum of 2 quarters · filed 2021-11-12
$116.54K
derived: sum of 3 quarters · filed 2021-11-12
$137.26K
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30$75.10K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28
$95.82K
derived: sum of 2 quarters · filed 2021-09-28
$116.54K
derived: sum of 3 quarters · filed 2021-09-28
$300.42K
10-K · filed 2021-09-28
2020-03-31$20.72K
10-Q · filed 2021-05-14
$41.44K
derived: sum of 2 quarters · filed 2021-05-14
$225.31K
10-Q · filed 2021-05-14
2019-12-31$20.72K
10-Q · filed 2021-02-12
$150.21K
10-Q · filed 2021-02-12
2019-09-30$114.90K
10-Q · filed 2020-11-16
2018-06-30$25.09K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-17
$186.39K
derived: sum of 2 quarters · filed 2018-09-17
$351.27K
derived: sum of 3 quarters · filed 2018-09-17
$516.15K
10-K · filed 2018-09-17
2018-03-31$161.30K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-10
$326.18K
derived: sum of 2 quarters · filed 2018-05-10
$491.06K
10-Q · filed 2018-05-10
2017-12-31$164.88K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-09
$329.76K
10-Q · filed 2018-02-09
2017-09-30$164.88K
10-Q · filed 2017-11-09
2017-06-30$1.69M
10-K · filed 2018-09-17
2016-06-30$1.72M
10-K · filed 2017-09-28
2014-03-31$299.74K
10-Q · filed 2014-05-20
2013-12-31$0.00
derived: 10-Q 75 month − 10-Q 72 month · filed 2014-02-14
$299.74K
10-Q · filed 2014-02-14
2013-09-30$299.74K
10-Q · filed 2013-11-14
2013-06-30$299.74K
10-K · filed 2013-10-15
2013-03-31$0.00
derived: 10-Q 66 month − 10-Q 63 month · filed 2013-05-20
$0.00
derived: sum of 2 quarters · filed 2013-05-20
$0.00
derived: sum of 3 quarters · filed 2013-05-20
$0.00
derived: sum of 4 quarters · filed 2013-05-20
$299.74K
10-Q · filed 2013-05-20
2012-12-31$0.00
derived: 10-Q 63 month − 10-Q 60 month · filed 2013-02-20
$0.00
derived: sum of 2 quarters · filed 2013-02-20
$0.00
derived: sum of 3 quarters · filed 2013-02-20
$0.00
derived: sum of 4 quarters · filed 2013-02-20
$299.74K
10-Q · filed 2013-02-20
2012-09-30$0.00
derived: 10-Q 60 month − 10-K 57 month · filed 2012-11-19
$0.00
derived: sum of 2 quarters · filed 2012-11-19
$0.00
derived: sum of 3 quarters · filed 2012-11-19
$299.74K
10-Q · filed 2012-11-19
2012-06-30$0.00
derived: 10-K 57 month − 10-Q 54 month · filed 2012-10-15
$0.00
derived: sum of 2 quarters · filed 2012-10-15
$299.74K
10-K · filed 2012-10-15
2012-03-31$0.00
derived: 10-Q 54 month − 10-Q/A 51 month · filed 2012-05-21
$299.74K
10-Q · filed 2012-05-21
2011-12-31$0.00
10-Q/A · filed 2012-03-07
$299.74K
10-Q/A · filed 2012-03-07
2010-12-31$0.00
10-Q/A · filed 2012-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
NANOVIRICIDES, INC. (NNVC)United States$0.031B
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45